Dionisia Quiroga, DO, PhD, FASCO
@quirogad.bsky.social
Breast medical oncologist & assistant professor @OSUCCC_James
Opinions expressed are my own
She/Her/Ella #bcsm #OncSky #MedSky
Opinions expressed are my own
She/Her/Ella #bcsm #OncSky #MedSky
Thank you so much for this honor!
Volunteering with @ascocancer.bsky.social has been a big joy in my career and happy to continue many future years of service!
Volunteering with @ascocancer.bsky.social has been a big joy in my career and happy to continue many future years of service!
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction: brnw.ch/21wUiSd
Learn more about FASCO distinction: brnw.ch/21wUiSd
July 21, 2025 at 3:16 PM
Thank you so much for this honor!
Volunteering with @ascocancer.bsky.social has been a big joy in my career and happy to continue many future years of service!
Volunteering with @ascocancer.bsky.social has been a big joy in my career and happy to continue many future years of service!
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction: brnw.ch/21wUiSd
Learn more about FASCO distinction: brnw.ch/21wUiSd
July 21, 2025 at 1:59 PM
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction: brnw.ch/21wUiSd
Learn more about FASCO distinction: brnw.ch/21wUiSd
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Thanks to these wonderful running buddies @drgattimays.bsky.social & @quirogad.bsky.social & @oncoalert.bsky.social for making it all happen!!
@oncoalert.bsky.social annual #ASCO25 5K on a beautiful morning in Chicago! Had some great running partners this am @quirogad.bsky.social @christeeny513.bsky.social
May 31, 2025 at 1:00 PM
Thanks to these wonderful running buddies @drgattimays.bsky.social & @quirogad.bsky.social & @oncoalert.bsky.social for making it all happen!!
Perfect #ASCO25 morning - beautiful Chicago lakeside run with two amazing leaders in breast cancer care and advocacy 🏃♀️🙏🏽 @christeeny513.bsky.social @drgattimays.bsky.social @oncoalert.bsky.social @ascocancer.bsky.social
@oncoalert.bsky.social annual #ASCO25 5K on a beautiful morning in Chicago! Had some great running partners this am @quirogad.bsky.social @christeeny513.bsky.social
May 31, 2025 at 1:01 PM
Perfect #ASCO25 morning - beautiful Chicago lakeside run with two amazing leaders in breast cancer care and advocacy 🏃♀️🙏🏽 @christeeny513.bsky.social @drgattimays.bsky.social @oncoalert.bsky.social @ascocancer.bsky.social
Dr. Dionisia Quiroga shares her tips for making #ASCO25 a networking triumph for early-career oncology professionals: brnw.ch/21wSSRC
May 23, 2025 at 5:22 PM
#ASCO25 is right around the corner!
✨With >40K registrants, how can you best stand out of the crowd and make meaningful connections during the conference?✨
Here are some tips for trainees & early-career oncologists:
connection.asco.org/do/networkin...
@ascocancer.bsky.social @ascopost.bsky.social
✨With >40K registrants, how can you best stand out of the crowd and make meaningful connections during the conference?✨
Here are some tips for trainees & early-career oncologists:
connection.asco.org/do/networkin...
@ascocancer.bsky.social @ascopost.bsky.social
Networking at ASCO25: Strategies for Success
Dr. Dionisia Quiroga shares her tips for making the 2025 ASCO Annual Meeting a networking triumph for early-career oncology professionals.
connection.asco.org
May 2, 2025 at 1:03 AM
#ASCO25 is right around the corner!
✨With >40K registrants, how can you best stand out of the crowd and make meaningful connections during the conference?✨
Here are some tips for trainees & early-career oncologists:
connection.asco.org/do/networkin...
@ascocancer.bsky.social @ascopost.bsky.social
✨With >40K registrants, how can you best stand out of the crowd and make meaningful connections during the conference?✨
Here are some tips for trainees & early-career oncologists:
connection.asco.org/do/networkin...
@ascocancer.bsky.social @ascopost.bsky.social
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Today family picture with some of the 87 amazing faculty of our Division of Medical Oncology at The James CCC. Very honored to be part and lead this incredible team!
@OhioStateMedOnc
@OSUCCC_James
@OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social
@OhioStateMedOnc
@OSUCCC_James
@OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social
April 25, 2025 at 2:45 PM
Today family picture with some of the 87 amazing faculty of our Division of Medical Oncology at The James CCC. Very honored to be part and lead this incredible team!
@OhioStateMedOnc
@OSUCCC_James
@OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social
@OhioStateMedOnc
@OSUCCC_James
@OhioStateMed @drgattimays.bsky.social @stoverlab.bsky.social
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Honored and grateful for the opportunity to discuss 3 oral abstracts at #ASCO25 and represent #OSUCCC @osucccjames.bsky.social @osuwexmed.bsky.social #Immunotherapy @sitcancer.bsky.social #PIIO @ascocancer.bsky.social
April 23, 2025 at 9:51 PM
Honored and grateful for the opportunity to discuss 3 oral abstracts at #ASCO25 and represent #OSUCCC @osucccjames.bsky.social @osuwexmed.bsky.social #Immunotherapy @sitcancer.bsky.social #PIIO @ascocancer.bsky.social
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social
Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD L1 Metastatic Triple Negativ...
Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD L1 Metastatic Triple Negativ...
www.gilead.com
April 21, 2025 at 11:14 PM
Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social
My hometown 🙏🏽
Vaccinations work; please protect yourself and others
Vaccinations work; please protect yourself and others
Measles case in Michigan reported. A baby may have exposed a lot of people recently.
April 16, 2025 at 2:59 PM
My hometown 🙏🏽
Vaccinations work; please protect yourself and others
Vaccinations work; please protect yourself and others
Reposted by Dionisia Quiroga, DO, PhD, FASCO
🚨We are hiring Medical Oncologists at @OhioStateMedOnc !
Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence
Send your applications
@OSUCCC_James @OhioStateMed
Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence
Send your applications
@OSUCCC_James @OhioStateMed
April 9, 2025 at 11:37 PM
🚨We are hiring Medical Oncologists at @OhioStateMedOnc !
Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence
Send your applications
@OSUCCC_James @OhioStateMed
Check the QR code below for the available positions! 3 pathways:
- Physician Scientist
- Clinical Scholar
- Clinical Excellence
Send your applications
@OSUCCC_James @OhioStateMed
Reposted by Dionisia Quiroga, DO, PhD, FASCO
From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA
March 22, 2025 at 10:44 AM
From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Cancer researchers working on health disparities say President Trump's actions could hurt rural whites, who lag behind other groups in cancer screening.
Trump wants to erase DEI. Researchers worry it will upend work on health disparity
Cancer researchers working on health disparities say President Trump's actions could hurt rural whites, who lag behind other groups in cancer screening.
www.npr.org
March 21, 2025 at 6:15 PM
Cancer researchers working on health disparities say President Trump's actions could hurt rural whites, who lag behind other groups in cancer screening.
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Deadline approaching! The #SITC Women in Cancer Immunotherapy Network Leadership Institute applications close March 24. Don’t miss your opportunity to participate in panel discussions and presentations from experienced female leaders. Learn more here: www.sitcancer.org/professional...
March 18, 2025 at 1:55 PM
Deadline approaching! The #SITC Women in Cancer Immunotherapy Network Leadership Institute applications close March 24. Don’t miss your opportunity to participate in panel discussions and presentations from experienced female leaders. Learn more here: www.sitcancer.org/professional...
Reposted by Dionisia Quiroga, DO, PhD, FASCO
NIH indirects case update:
Hearing ongoing now, and I'll try to live tweet some notable exchanges.
Prior to more detailed arguments, Judge Kelley starts off with a few point questions to both sides:
(I'm paraphrasing here)
Hearing ongoing now, and I'll try to live tweet some notable exchanges.
Prior to more detailed arguments, Judge Kelley starts off with a few point questions to both sides:
(I'm paraphrasing here)
February 21, 2025 at 3:19 PM
NIH indirects case update:
Hearing ongoing now, and I'll try to live tweet some notable exchanges.
Prior to more detailed arguments, Judge Kelley starts off with a few point questions to both sides:
(I'm paraphrasing here)
Hearing ongoing now, and I'll try to live tweet some notable exchanges.
Prior to more detailed arguments, Judge Kelley starts off with a few point questions to both sides:
(I'm paraphrasing here)
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Discuss real-world case studies with clinical experts! #SITC’s ACI: Women’s Malignancies program will explore practical insights to apply immunotherapy into clinical practice. Join Feb. 28 for a free CME program. Register now: ow.ly/bTFn50UYy9j
@drgattimays.bsky.social @veredstearns.bsky.social
@drgattimays.bsky.social @veredstearns.bsky.social
February 12, 2025 at 3:12 PM
Discuss real-world case studies with clinical experts! #SITC’s ACI: Women’s Malignancies program will explore practical insights to apply immunotherapy into clinical practice. Join Feb. 28 for a free CME program. Register now: ow.ly/bTFn50UYy9j
@drgattimays.bsky.social @veredstearns.bsky.social
@drgattimays.bsky.social @veredstearns.bsky.social
Reposted by Dionisia Quiroga, DO, PhD, FASCO
In Ohio during FY23 (2022-2023) this was the impact of NIH funding:
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
NIH In Your State - United For Medical Research
Select a state on the map to see the impact of NIH funding across America.
www.unitedformedicalresearch.org
February 8, 2025 at 12:20 PM
In Ohio during FY23 (2022-2023) this was the impact of NIH funding:
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
$1.01 Billion in grants and contracts
$2.05 Billion in economic support
13,061 jobs supported
This reduction in NIH indirect will decimate research and limit health care advances
www.unitedformedicalresearch.org/nih-in-your-...
Reposted by Dionisia Quiroga, DO, PhD, FASCO
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 12:18 AM
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Great session with Dr Heather McArthur on treating early stage #TNBC #IO posted on #ReachMD @osuwexmed.bsky.social @osucccjames.bsky.social reachmd.com/programs/cme...
Virtual Tumor Board: Maximizing the Potential of Immuno-Oncology in Early TNBC Through Personalized Care
Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and ...
reachmd.com
February 7, 2025 at 1:13 AM
Great session with Dr Heather McArthur on treating early stage #TNBC #IO posted on #ReachMD @osuwexmed.bsky.social @osucccjames.bsky.social reachmd.com/programs/cme...
Reposted by Dionisia Quiroga, DO, PhD, FASCO
200 participants at OSU SABCS meeting - Christian Rolfo @christianrolfo.bsky.social
@stoverlab.bsky.social
@quirogad.bsky.social
oncodaily.com/blog/237555
#BreastCancer #Cancer #FightAgainstCancer #MedOnc #OncoDaily #Oncology #OSU #SABCSmeeting #Medicine #Health
@stoverlab.bsky.social
@quirogad.bsky.social
oncodaily.com/blog/237555
#BreastCancer #Cancer #FightAgainstCancer #MedOnc #OncoDaily #Oncology #OSU #SABCSmeeting #Medicine #Health
Christian Rolfo: 200 participants at OSU SABCS meeting - OncoDaily
Christian Rolfo: 200 participants at OSU SABCS meeting / Breast Cancer, cancer, Christian Rolfo, Daniel Stover, Dionisia Quiroga, fight against cancer, Global
oncodaily.com
February 4, 2025 at 4:48 PM
200 participants at OSU SABCS meeting - Christian Rolfo @christianrolfo.bsky.social
@stoverlab.bsky.social
@quirogad.bsky.social
oncodaily.com/blog/237555
#BreastCancer #Cancer #FightAgainstCancer #MedOnc #OncoDaily #Oncology #OSU #SABCSmeeting #Medicine #Health
@stoverlab.bsky.social
@quirogad.bsky.social
oncodaily.com/blog/237555
#BreastCancer #Cancer #FightAgainstCancer #MedOnc #OncoDaily #Oncology #OSU #SABCSmeeting #Medicine #Health
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Dr. Quiroga, we're delighted to have you on the expert panel and look forward to your presentation on immunotherapy for late-stage breast cancer!
📚🎙️Come discuss updates and the future of IO use in #MBC with me on Feb 28th!
A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social
A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social
#Immunotherapy for women’s malignancies continue to evolve. #SITC’s ACI: A Focus on Women’s Malignancies program provides clinicians with current updates in the use of IO to treat early/late-stage breast cancer. Join Feb. 28.
Register: www.sitcancer.org/education/ac...
#LearnACI #breastcancer
Register: www.sitcancer.org/education/ac...
#LearnACI #breastcancer
February 3, 2025 at 3:09 PM
Dr. Quiroga, we're delighted to have you on the expert panel and look forward to your presentation on immunotherapy for late-stage breast cancer!
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer - Breast Cancer Research
Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment...
breast-cancer-research.biomedcentral.com
February 3, 2025 at 11:18 PM
Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm
Reposted by Dionisia Quiroga, DO, PhD, FASCO
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
February 3, 2025 at 11:48 AM
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
ASCO Daily News: Advances in Adjuvant Therapy for High-Risk Early Breast Cancer With Germline Mutations
Dr. Jessica Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and BRCA1/2 mutations, including how to identify patients who should receive gen...
ascodaily.libsyn.com
February 2, 2025 at 7:44 PM
🎉Reunion w/ my co-fellow @jasminesukumar.bsky.social @mdanderson.bsky.social to discuss early #breastcancer adj tx w/ path germline muts on the @ascocancer.bsky.social Daily News podcast
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
👉Who needs testing?
👉OLYMPIA updates
👉Concurrent PARPi use w/ other adj tx
ascodaily.libsyn.com/advances-in-...
📚🎙️Come discuss updates and the future of IO use in #MBC with me on Feb 28th!
A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social
A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social
#Immunotherapy for women’s malignancies continue to evolve. #SITC’s ACI: A Focus on Women’s Malignancies program provides clinicians with current updates in the use of IO to treat early/late-stage breast cancer. Join Feb. 28.
Register: www.sitcancer.org/education/ac...
#LearnACI #breastcancer
Register: www.sitcancer.org/education/ac...
#LearnACI #breastcancer
February 2, 2025 at 2:59 AM
📚🎙️Come discuss updates and the future of IO use in #MBC with me on Feb 28th!
A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social
A++ group of #breastonc #gynonc speakers and great opportunity for CME/MOC and other ed credits
@sitcancer.bsky.social
#LearnACI #bcsm @drgattimays.bsky.social @osucccjames.bsky.social